Reddit Posts
Made some okay investments - Thought someone may be interested?
Trading pharmaceutical stock options around FDA announcements (drug approval/rejection)
FDA to back accelerated approval pathway for gene therapies (NASDAQ:SRPT)
Hot Stocks: XPEV rises on earnings; MARA, MSTR, RIOT boosted by BTC price; FRC, SRPT slide
Hot Stocks: TUP, ANF slump on financial figures; DUOL surges; SRPT climbs on FDA decision
$REV - Hey morons, tired of the fucking trust me bro squeeze ? Check thats's sexy DD !
$REV - Hey morons, tired of the trust me bro squeeze ? Check thats's sexy DD !
Three Biotech Stocks That Could Rise 90% or More, According to Motley Fool
Will AGC see SRPT like rip Monday if they drop merger date in PM?
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street Experts, per Motley Fool
Congrats to all those who stuck with Golden Nugget / Portfolio update
Congrats to all those who stuck with GNOG / Portfolio update
CALLING ALL APES!!!! $SRPT Time to jump in this is going to be big lets make it as big as $GME.
$SRPT this stock is set to squeeze up 26% so far today time to jump in.
Actionable Trading MRNA SRPT CRSP GSK PFE MODERNA HITS $100 Billion GENE RNA MED
Mentions
Personally I have significant long positions in TARS, NBIX and ABBV (although note I’ve been in these over a year and am not adding at these levels). I also hold SRPT and QURE. SRPT I also bought near book value when it was in the 13s QURE is a good example of biotech. Everything looked good and they were aligned with FDA on the trial design. Then last minute FDA reversed course and it’s now down 50% from my cost basis. But I sized accordingly given the historical control uncertainty so the damage isn’t too bad…
Congrats on getting back to breakeven, that’s huge. One thought: instead of relying only on 0DTE tape trades, mixing in event-driven swings can really help smooth the ride. Names like SRPT are a good example; defined catalysts (FDA updates, Cohort 8 progress, newborn screening tailwinds) give you asymmetric setups where time can actually work for you, not against you like with 0DTE.
What’s interesting is SRPT showing up as “cheap calls” while the company just pushed debt maturities to 2030, and has newborn screening momentum in its favor.
Clean trade. Congratssss! I’m riding a couple longer-biased names too… SRPT’s been showing signs of life again, so I’m giving that one some room.
Sarepta (SRPT). Years of conducting poor studies on a questionably effective drug and gaslighting patients' families into pleading to the FDA for approval finally caught up to them.
Lmao im up on my longs… SRPT and ANET. I wish it wasnt pure luck and i had it down to a science.
Holy fuck, just saw SRPT. RIP. Numbers look good; wtf happened.
We definitely need clarity on rate cuts. Overall I took a huge gut punch the past week (QURE and SRPT kicked all of biotech in the nuts). Feel good about the rest. Will try to buy some dips
I love betting against SRPT I should have played earnings for this one
I guess SRPT just goes straight to 0, ouch 🤕
Whoever did puts for SRPT is a very happy person right now. I was considering it but have PTSD from biotech shit.
These are the days picking Pennies in front of a stream roller makes sense. $SRPT
Biotech is so fun. It's an insiders dream. Look at SRPT and QURE. I wish I was one of the patients in phase 3 clinical trials. I'd fake a cough and make these bulls lose billions.
HC Wainright set a price target of $0 for SRPT wtf?
SRPT was the lotto millionaire maker with -36%
I've gotten out of SRPT a while ago with profit and thank god for that what the fuck
SRPT could be cheap to buy now
SRPT went off a bridge on an earnings beat of 70%
FDA is so insanely corrupt. In fact, every single cabinet is led by just self-centered power hungry morons. FDA agreed to a trial design for QURE. They ran the trial for 3 years. It is proven to work in Huntington’s disease which has no treatment available. Dumbass Vinay Prasad comes in and makes it about himself and his ideology again. Just like he did with SRPT. Absolute dysfunction
I’m in for SRPT earnings tomorrow. What’s the worst that could happen. I’m good with my hands and could always make it back the old fashioned way.
Long $NVO, $HIMS, $UBER, $SRPT, $HOOD
SRPT earnings Monday after hours. Company was hammered by FDS but showing some life. Big gap to fill from $24 to $36 if good earnings. A true gamble though
Gotta add more on SRPT . With all the hype about that patient pool expansion news this week, I'm thinking the stock is coiling up. Earnings are next Monday, November 3rd, after the market closes.
$SRPT They announced earnings report will be early, next Monday AH instead Wed, going to be good! Will beat and expecting good stuff with it. See the SRPT board for DD.
SRPT earning Monday after hours. Potential to gap fill to 36.
I'm looking at $NTLA as well. One thing I don't like is that stock recovery isn't 100% post-event. I might trade sideways for a bit before moving back up. Examples below didn't really recover and still well below pre-event. Some concerns chatGPT shared with me: Here are a few recent situations that closely map to the scenario you’re dealing with (lead asset, trial pause, safety event) — with how they played out. • Rocket Pharmaceuticals (RCKT) – gene therapy for Danon disease A patient in their Phase 2 pivotal trial (RP-A501) died following a capillary-leak syndrome and acute systemic infection. → The trial was voluntarily paused and the FDA placed a hold. → Stock plunged \~60% intraday. → Later resumed with lower dose; stock recovered \~20% but stayed below prior levels. Takeaway: Safety event ⇒ big drop; resumption ⇒ partial rebound. • Sarepta Therapeutics (SRPT) – gene therapy for Duchenne muscular dystrophy (DMD) Two patient deaths from acute liver failure triggered a pause in shipments and trials. → Stock dropped >40% on the news. Takeaway: Even approved products face serious valuation risk after safety events. • Novavax (NVAX) – vaccine candidate trial hold A motor-neuropathy case in a Phase 2 trial led to an FDA clinical hold. → Stock dropped \~19%. Takeaway: Safety issue in even lower-risk areas causes sharp market reactions. • Intellia Therapeutics (NTLA) One patient developed Grade 4 liver enzyme elevation → company paused dosing in Phase 3 MAGNITUDE trial of nex-z. → Shares fell \~45% pre-market. Important nuance: single patient (\~450+ dosed), appears reversible but still triggered protocol pause. Watch: causality, regulator feedback, protocol changes, resumption timeline.
Not following Shkreli at all. looking at the data. SRPT’s clinical results continue to show meaningful benefit, real-world evidence is building, and the commercial rollout is progressing with increasing revenue and broadening distribution. All of that together explains why it remains on my radar, and in my opinion, incredibly undervalued. There is plenty of public information to support this.
$SRPT situation looks quite nice. Going towards the earnings report on November 5. Many strong catalysts coming up billions in revenue while essentially trading at .8. Great clinical data, continuing market penetration income from Roche is increasing as well as their international distributor. This temporary beat down from the highs is going away. Everything looks great, definitely biotech. Will be swinging while we do the trip back north, but it’s looking really good short term as well.
Well, you can go to the SRPT further due diligence. Best of luck to us all!
Ok I already bought SRPT. Your turn to pump it for me
$SRPT is quietly shifting from retail-heavy sentiment to broader institutional interest institutions don’t create products around names they don’t believe will move ... this could mark the start of a bigger liquidity and visibility phase for Sarepta.
$SRPT will keep being Green going into earnings November 5!
$SRPT on its way back up long way to go! Been trending well and earnings come out November 5 which will be a beat
$SRPT with a low $340 M expected revenues coming into earnings that will be posted on November 5, they are going to crush it. And the basic math also says they’ll have a strong Q4 given their current official guidance, (2.3-2.6B for year) which has not changed since the major over correction that happened over the summer. They have just presented amazing clinical data at the world conference last week that can assuage safety concerns and they continue to increase revenues into the billions. A strong commercial pipeline for a commercial stage biotech should be trading about 5-10 times multiple and they are only trading at an anemic .9. It would be worthwhile for folks to do their due diligence on this one.
[SRPT Fall 2025 Investor Deck](https://investorrelations.sarepta.com/static-files/54793bd6-09b6-4c68-8281-39e586071e88) Good question: for gene therapies the per-patient list price is often in the millions. For example, Sarepta priced Elevidys at $3.2M/patient and Zolgensma launched around $2.1M. These are typically one-time infusions for very small populations (DMD prevalence is ~1 in 3,500–5,000 boys), so you end up multiplying a million-plus price by thousands (not millions) of patients. Keep in mind those are list prices net revenue after payer discounts and access limits can be a lot lower, but even then a few thousand treated patients can equal billions in revenue on paper. I’m attaching their fall 2025 investor deck that was just updated before the world clinical conference a week ago, if you’re willing to take the time to look through it, it’s gonna give you all the answers!
$SRPT, Earnings after market Nov 5th, there will certainly be news along with it if we don’t see news before then. Pretty sure the general consensus is the expected earnings is set low, and they will pretty much crush it again. The big investors certainly have more of an inside track and speak directly with management. We can expect several Green days in a row probably this entire week just like we saw the run up before the conference. It’s too risky to bring it down at this point, so hopefully by the time we hit November 5, we’re sitting in the high 20s or low 30s. For now daily greens are very healthy!
CIFR & SRPT darling
$SRPT great Clinical data continues to come in from the world conference. Saturday’s data will be the most important and they’ve introduced a couple of late breaking items, no late breaking items are ever introduced unless they’re good…
$SRPT with a GAPING gap up to $36. All she needs is some volume and she's off to the races. https://preview.redd.it/syu7hyjy05uf1.png?width=2352&format=png&auto=webp&s=d9a2839a1f5063c0e6a6248faa7b747a1de4c42e
$SRPT the battle continues, but we are winning! Great clinical data today and the rest of the week and earnings on November 5, stock is still incredibly undervalued for a commercial stage biotech bringing in billions and revenue with multiple product lines and great clinical data coming in from all their trials.
$SRPT & $RCKT for my biotech bros
GLXY, METC, APLD (earnings tomorrow), PATH, BMNR, SRPT...I could do this all day
I believe SRPT is going to make me a couple bucks. It’s just what I believe.
For this week into next week remember: Buy some SRPT. Buy Gold and Silver. Buy ZVRA (spec size). Buy POET (idk - this is pure gamble but I got a feeling).
Why did SRPT just rocket
$SRPT clinical data discussion starts an hour before market tomorrow, and then throughout the rest of the week at the world conference, looking forward to hearing what they gotta say very exciting time for the company in this temporary heavily discounted situation
$SRPT clinical data presentation start tomorrow!
I gotta find one more Valhalla size position for SRPT
$SRPT , and it’s not even close. 🚀🌕
If you want a real gamble, buy Nov SRPT calls
Watching $SRPT closely this week .. conference data coming up and momentum building after last week’s strong move. Could be one of the more interesting tickers in this thread.
$SRPT presenting a lot of data at the world conference this week, already incredibly undervalued for a commercial stage biotech bringing in billions, artificially hammered it down, gaining momentum again quite nicely
He still made a profit after averaging down. SRPT is a great play once the FDA FUD dies down
I’m waiting for the posts in 2 months why everyone missed PL + SRPT. Also can we get Plug back to 30?
My SRPT and SMCI plays hit this week. Not sure what to do with this cash burning a hole in my pocket.
SRPT had a rip today too. ER going to be rocket.
If XLV and SPY stay bullish, Healthcare stocks. MRK, MRNA, RXRX, CNC, SRPT all on the radar. I'll figure out which one/s based on the morning price action.
SRPT big data release in a week. It’s got an FDS suspension for s gene therapy drug bc the guy Trump hired is an effing retard. It could recover $20. INTC always a safe bet because they keep sweeping call options. I got some MLTX for a squeeze.
SRPT is the next Valhalla play. Get in for insanity next week/end
$SRPT doin tricks on it. full squeeze coming off this $22 shelf. YUR
Guys please buy a little SRPT before the weekend. Just a few shares or a couple of calls. Please
Do I hold my 200 SRPT shares or dump it all before close?
Among others I'm holding ONDS, NBIS and SRPT. Portfolio pumping +12% in a day out of pretty much nowhere.
Sold my SRPT 22.5 Jan 16 calls yesterday for a loss. Must've forgot to put my helmet on.
SRPT shorts throwing their hats on the ground, stomping on them, yelling dagnabbit, etc
I think SRPT is one of the most promising